Jonathan Stine, MD
Gastroenterology · Hershey, PANPI 1932333440
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,240 of the $9,759 with a category attached, or 84.4%. Madrigal Pharmaceuticals accounts for 83.8% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $8,139, 6.8 times the $1,190 reported in 2023.
Across 20 payments — averaging $487.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$8K
- Novo Nordisk$1K
- AstraZeneca$347
- Novo Nordisk US Research & Development, Inc.$17
Across 223 payments — averaging $1984.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Shared Services North America, Inc.$224K
- Astrazeneca UK Limited$140K
- AstraZeneca$37K
- Regeneron$36K
- Boehringer Ingelheim International GmbH$4K
- Novo Nordisk AS$2K
- plus $780 from 1 others
What the payments were for
- Consulting fees$8,24084%
- Travel & lodging$7418%
- Food & beverage$7788%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 11 | $8,182 |
| Novo Nordisk | 3 | $1,212 |
| AstraZeneca | 5 | $347 |
| Novo Nordisk US Research & Development, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$7,964
How this compares
$9,759 in reported general payments places this provider in the 80th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 53 | $164,572 |
| RezdiffraResmetirom | 21 | $126,173 |
| Everolimus | 11 | $24,940 |
| Mycophenolic AcidMycophenolate Sodium | 68 | $16,093 |
| Tacrolimus | 89 | $10,512 |
| Ursodiol | 31 | $9,093 |
| Mycophenolate Mofetil | 32 | $2,778 |
| Tenofovir Disoproxil Fumarate | 15 | $1,268 |
| Lactulose | 21 | $1,078 |
| GengrafCyclosporine, Modified | 11 | $792 |
| Carvedilol | 64 | $599 |
| Spironolactone | 19 | $565 |
| Omeprazole | 38 | $331 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 12 | $330 |
| Hydrocortisone | 21 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Madrigal PharmaceuticalsRezdiffra | $8,182 | $126,17321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Hershey
- Kofi ClarkeHershey$426K
- Andrew TinsleyHershey$322K
- Emmanuelle WilliamsHershey$212K
- Quaadir Otto-SmallwoodHershey$63K
- Karen KrokHershey$54K
- Miguel RegueiroPittsburgh$1.5M
- Adam PeytonAllentown$985K
- Shahin RahimianWaynesboro$592K
- Sandra El-HachemPittsburgh$472K
- Harshit KharaDanville$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.